Skip to content

森先特科技

US · SXT #2027 按市值排名 上市于 1970
133.74 +0.32 +0.24%
实时 - 追踪5344个代码 - 心跳于244秒前 · 2026-10-16 19:30

最新新闻

  • UBS Maintains Sensient Technologies(SXT.US) With Buy Rating, Maintains Target Price $143
    \u5e02\u573a\u8d44\u8baf · 2026/7/6
  • UBS Maintains Sensient Technologies(SXT.US) With Buy Rating, Raises Target Price to $157
    \u5e02\u573a\u8d44\u8baf · 2026/9/30
  • 评级变动
    Baird Maintains Sensient Technologies(SXT.US) With Buy Rating, Raises Target Price to $125
    \u5e02\u573a\u8d44\u8baf · 2025/7/4
  • 公司公告
    China SXT Pharmaceuticals | SC 13G: Statement of acquisition of beneficial ownership by individuals-Streeterville Capital LLC(9.99*%),Streeterville Management LLC(9.99*%), etc.
    SEC · 2023/3/30
  • 公司公告
    China SXT Pharmaceuticals | SC 13G: Statement of acquisition of beneficial ownership by individuals-Streeterville Capital LLC(9.99*%),Streeterville Management LLC(9.99*%), etc.
    SEC · 2022/8/26
  • Baird Maintains Sensient Technologies(SXT.US) With Buy Rating, Announces Target Price $140
    \u5e02\u573a\u8d44\u8baf · 2026/7/27
  • 公司公告
    China SXT Pharmaceuticals | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Streeterville Capital LLC(0%),Streeterville Management LLC(0%), etc.
    SEC · 2023/3/30
  • Rothschild & Co Redburn Initiates Sensient Technologies(SXT.US) With Hold Rating, Announces Target Price $125
    \u5e02\u573a\u8d44\u8baf · 2026/7/8
  • 公司公告
    China SXT Pharmaceuticals | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Streeterville Capital LLC(9.99%),Streeterville Management LLC(9.99%), etc.
    SEC · 2024/10/26
  • 评级变动
    Baird Maintains Sensient Technologies(SXT.US) With Buy Rating, Raises Target Price to $93
    \u5e02\u573a\u8d44\u8baf · 2025/4/29
  • 评级变动
    Baird: Maintaining the Sensient Technologies (SXT.US) rating, adjusted from better than market to better than market rating, and adjusted the target price from $70.00 to $80.00.
    Zhitong Finance · 2024/4/29
  • 公司公告
    China SXT Pharmaceuticals | SC 13G: Statement of acquisition of beneficial ownership by individuals-Lind Global Fund II LP(9.9%),Lind Global Fund II LLC(9.9%), etc.
    SEC · 2022/1/22
  • 评级变动
    Baird Maintains Sensient Technologies(SXT.US) With Buy Rating, Maintains Target Price $85
    \u5e02\u573a\u8d44\u8baf · 2024/10/28
  • 评级变动
    Baird Maintains Sensient Technologies(SXT.US) With Buy Rating, Raises Target Price to $85
    \u5e02\u573a\u8d44\u8baf · 2024/7/29
  • UBS Maintains Sensient Technologies(SXT.US) With Buy Rating, Raises Target Price to $155
    \u5e02\u573a\u8d44\u8baf · 2026/7/27
  • 评级变动
    UBS Initiates Sensient Technologies(SXT.US) With Buy Rating, Announces Target Price $115
    \u5e02\u573a\u8d44\u8baf · 2026/4/1
  • 评级变动
    UBS Maintains Sensient Technologies(SXT.US) With Buy Rating, Raises Target Price to $143
    \u5e02\u573a\u8d44\u8baf · 2026/4/28

新闻标题为自动聚合内容,未经我们团队独立核实或编辑。

报价时间 2026-10-16 19:30:05 · 仅供参考,不构成投资建议,也未考虑您的具体情况。

森先特科技 讨论区 0 条评论

发表评论